Comparative Pharmacology
Head-to-head clinical analysis: HYDRO RIDE versus ORETIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDRO RIDE versus ORETIC.
HYDRO-RIDE vs ORETIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide diuretic that inhibits sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water.
Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, reducing reabsorption of sodium and chloride, leading to increased excretion of water and electrolytes.
Initiate at 12.5-25 mg orally once daily. Titrate to 50-100 mg once daily. Maximum 200 mg per day.
25-100 mg orally once or twice daily; maximum 200 mg/day.
None Documented
None Documented
Terminal half-life 4-6 hours (prolonged in renal impairment).
Terminal elimination half-life: 6-15 hours (average 10 hours); prolonged in renal impairment and heart failure; clinical context: duration of diuretic effect correlates with half-life, requiring once or twice daily dosing.
Primarily renal (50% unchanged; remainder as glucuronide conjugate); biliary/fecal <10%.
Renal: approximately 95% (primarily as unchanged drug via tubular secretion), Biliary/fecal: <5%
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic